Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hepatitis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 296 articles:
HTML format



Single Articles


    January 2022
  1. MAWATARI S, Kumagai K, Oda K, Tabu K, et al
    Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
    PLoS One. 2022;17:e0262267.
    PubMed     Abstract available


  2. BOODRAM B, Mackesy-Amiti ME, Khanna A, Brickman B, et al
    People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.
    PLoS One. 2022;17:e0248850.
    PubMed     Abstract available


  3. SUZUKI K, Suda G, Yamamoto Y, Abiko S, et al
    Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
    PLoS One. 2022;17:e0261760.
    PubMed     Abstract available


  4. MBAGA DS, Kenmoe S, Kengne-Nde C, Ebogo-Belobo JT, et al
    Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.
    PLoS One. 2022;17:e0262903.
    PubMed     Abstract available


  5. BALIASHVILI D, Averhoff F, Kasradze A, Salyer SJ, et al
    Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.
    PLoS One. 2022;17:e0262935.
    PubMed     Abstract available


  6. OCAN M, Acheng F, Otike C, Beinomugisha J, et al
    Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.
    PLoS One. 2022;17:e0262126.
    PubMed     Abstract available


  7. MORSICA G, Galli L, Messina E, Castagna A, et al
    Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
    PLoS One. 2022;17:e0262917.
    PubMed     Abstract available


  8. JOLLY PE, Akinyemiju TF, Sakhuja S, Sheth R, et al
    Association of aflatoxin B1 levels with mean CD4 cell count and uptake of ART among HIV infected patients: A prospective study.
    PLoS One. 2022;17:e0260873.
    PubMed     Abstract available


  9. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2022;17:e0263654.
    PubMed     Abstract available


  10. LAMORI J, Feng X, Pericone CD, Mesa-Frias M, et al
    Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults.
    PLoS One. 2022;17:e0264062.
    PubMed     Abstract available


  11. NAGURA Y, Matsuura K, Iio E, Fujita K, et al
    Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
    PLoS One. 2022;17:e0263844.
    PubMed     Abstract available


  12. DESTREMPES F, Gesnik M, Chayer B, Roy-Cardinal MH, et al
    Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.
    PLoS One. 2022;17:e0262291.
    PubMed     Abstract available


  13. KHAN M, Khan S, Gondal MF, Bibi S, et al
    Genetic diversity in enhancer II region of HBV genotype D and its association with advanced liver diseases.
    PLoS One. 2022;17:e0261721.
    PubMed     Abstract available


  14. NAGORNYKH AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG, et al
    Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.
    PLoS One. 2022;17:e0264266.
    PubMed     Abstract available


  15. LIM SH, Lee S, Lee YB, Lee CH, et al
    Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262990.
    PubMed     Abstract available


  16. ANTUAMWINE BB, Herchel ED, Bawa EM
    Comparative prevalence of hepatitis B virus infection among pregnant women accessing free maternal care in a tertiary hospital in Ghana.
    PLoS One. 2022;17:e0263651.
    PubMed     Abstract available


  17. SHRESTHA LB, Yadav GK, Pradhan S, Sharma A, et al
    Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal.
    PLoS One. 2022;17:e0264791.
    PubMed     Abstract available


  18. TAHERKHANI R, Farshadpour F
    Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
    PLoS One. 2022;17:e0265063.
    PubMed     Abstract available


  19. TATARA E, Gutfraind A, Collier NT, Echevarria D, et al
    Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    PLoS One. 2022;17:e0264983.
    PubMed     Abstract available


  20. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    PubMed     Abstract available


  21. TAKAURA K, Kurosaki M, Inada K, Kirino S, et al
    The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
    PLoS One. 2022;17:e0264075.
    PubMed     Abstract available


  22. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    PubMed     Abstract available


  23. UCHIDA Y, Nakao M, Yamada S, Tsuji S, et al
    Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
    PLoS One. 2022;17:e0262764.
    PubMed     Abstract available


  24. MAGGI P, Calo F, Messina V, Stornaiuolo G, et al
    Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.
    PLoS One. 2022;17:e0265178.
    PubMed     Abstract available


  25. KIMER N, Meldgaard M, Hamberg O, Kronborg TM, et al
    The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial.
    PLoS One. 2022;17:e0264278.
    PubMed     Abstract available


  26. CHOI SI, Cho Y, Ki M, Kim BH, et al
    Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts.
    PLoS One. 2022;17:e0265668.
    PubMed     Abstract available


  27. REINHARDT B, Taylor R, Dawkins C, Banks T, et al
    The use of dried blood spot cards to assess serologic responses of individuals vaccinated against measles, hepatitis A, tetanus, influenza and varicella zoster.
    PLoS One. 2022;17:e0265813.
    PubMed     Abstract available


  28. YAZDANI K, Dolguikh K, Zhang W, Shayegi-Nik S, et al
    Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    PLoS One. 2022;17:e0265811.
    PubMed     Abstract available


  29. TANA MM, Klepper A, Lyden A, Pisco AO, et al
    Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.
    PLoS One. 2022;17:e0264307.
    PubMed     Abstract available


  30. BURDETTE DL, Lazerwith S, Yang J, Chan HLY, et al
    Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
    PLoS One. 2022;17:e0262516.
    PubMed     Abstract available



  31. Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2022;17:e0266498.
    PubMed    



  32. Expression of Concern: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
    PLoS One. 2022;17:e0266497.
    PubMed    


  33. CHANDRA DEB L, Hove H, Miller TK, Pinks K, et al
    Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota.
    PLoS One. 2022;17:e0266047.
    PubMed     Abstract available


  34. XIA Z, Qin L, Ning Z, Zhang X, et al
    Deep learning time series prediction models in surveillance data of hepatitis incidence in China.
    PLoS One. 2022;17:e0265660.
    PubMed     Abstract available


  35. THI CAM HUONG N, Trung NQ, Luong BA, Tram DB, et al
    Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients.
    PLoS One. 2022;17:e0266134.
    PubMed     Abstract available


  36. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    PubMed     Abstract available


  37. SEYOUM E, Demissie M, Worku A, Mulu A, et al
    HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study.
    PLoS One. 2022;17:e0267230.
    PubMed     Abstract available


  38. AUMA AWN, Kowal C, Shive CL, Lange A, et al
    Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
    PLoS One. 2022;17:e0267512.
    PubMed     Abstract available


  39. MABUNDA N, Augusto O, Zicai AF, Duaja A, et al
    Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique.
    PLoS One. 2022;17:e0267472.
    PubMed     Abstract available


  40. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
    Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    PLoS One. 2022;17:e0267902.
    PubMed     Abstract available


  41. MANZOOR S, Khalid M, Idrees M
    P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis.
    PLoS One. 2022;17:e0259727.
    PubMed     Abstract available


  42. SSEKAMATTE T, Isunju JB, Mutyoba JN, Tetui M, et al
    Predictors of Hepatitis B screening and vaccination status of young psychoactive substance users in informal settlements in Kampala, Uganda.
    PLoS One. 2022;17:e0267953.
    PubMed     Abstract available


  43. GUZMAN-HOLST A, Luna-Casas G, Burguete Garcia A, Madrid-Marina V, et al
    Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study.
    PLoS One. 2022;17:e0268469.
    PubMed     Abstract available


  44. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
    Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0268180.
    PubMed     Abstract available


  45. O'DONNELL A, Pham N, Battisti L, Epstein R, et al
    Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
    PLoS One. 2022;17:e0268478.
    PubMed     Abstract available


  46. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    PubMed     Abstract available


  47. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
    Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
    PLoS One. 2022;17:e0268526.
    PubMed     Abstract available


  48. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2022;17:e0269049.
    PubMed     Abstract available


  49. FERNANDEZ VILLALOBOS NV, Kessel B, Rodiah I, Ott JJ, et al
    Seroprevalence of hepatitis E virus infection in the Americas: Estimates from a systematic review and meta-analysis.
    PLoS One. 2022;17:e0269253.
    PubMed     Abstract available


  50. KENFACK-MOMO R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, et al
    Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269250.
    PubMed     Abstract available


  51. DIAMOND T, Burn TN, Nishiguchi MA, Minichino D, et al
    Familial hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-gamma in a predominantly hepatic-intrinsic manner.
    PLoS One. 2022;17:e0269553.
    PubMed     Abstract available


  52. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
    Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    PLoS One. 2022;17:e0269641.
    PubMed     Abstract available


  53. MADEIRA F, Costa-Lopes R, Do Bu EA, Tato Marinho R, et al
    The role of stereotypical information on medical judgements for black and white patients.
    PLoS One. 2022;17:e0268888.
    PubMed     Abstract available


  54. SIEDLECKA M, Kublicka A, Wieliczko A, Matczuk AK, et al
    Molecular detection of avian hepatitis E virus (Orthohepevirus B) in chickens, ducks, geese, and western capercaillies in Poland.
    PLoS One. 2022;17:e0269854.
    PubMed     Abstract available


  55. ISUNJU JB, Wafula ST, Ndejjo R, Nuwematsiko R, et al
    Awareness of hepatitis B post-exposure prophylaxis among healthcare providers in Wakiso district, Central Uganda.
    PLoS One. 2022;17:e0270181.
    PubMed     Abstract available


  56. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
    Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
    PLoS One. 2022;17:e0264741.
    PubMed     Abstract available


  57. SONO S, Sae-Chan J, Kaewdech A, Chamroonkul N, et al
    HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program.
    PLoS One. 2022;17:e0270458.
    PubMed     Abstract available


  58. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    PubMed     Abstract available


  59. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    PubMed     Abstract available


  60. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    PubMed     Abstract available


  61. WOO HY, Heo J, Tak WY, Lee HJ, et al
    Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial.
    PLoS One. 2022;17:e0270716.
    PubMed     Abstract available


  62. WANG CH, Lin RC, Hsu HY, Tseng YT, et al
    Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study.
    PLoS One. 2022;17:e0271790.
    PubMed     Abstract available


  63. SAHIBZADA KI, Ganova-Raeva L, Dimitrova Z, Ramachandran S, et al
    Hepatitis C virus transmission cluster among injection drug users in Pakistan.
    PLoS One. 2022;17:e0270910.
    PubMed     Abstract available


  64. MATA-MARIN JA, de Pablos-Leal AA, Mauss S, Arroyo-Anduiza CI, et al
    Risk factors for HCV transmission in HIV-positive men who have sex with men in Mexico.
    PLoS One. 2022;17:e0269977.
    PubMed     Abstract available


  65. WAHOME PK, Kiende P, Nakazea RJ, Mwasowa NM, et al
    Occult hepatitis B virus infections and risk factors among school-going adolescent voluntary blood donors in Kwale County Kenya, January 2020-June 2021: Cross sectional study.
    PLoS One. 2022;17:e0263473.
    PubMed     Abstract available


  66. LAHOOD A, Rahman R, McKenna L, Frick M, et al
    Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
    PLoS One. 2022;17:e0271102.
    PubMed     Abstract available


  67. PISANO MB, Campbell C, Anugwom C, Re VE, et al
    Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.
    PLoS One. 2022;17:e0272809.
    PubMed     Abstract available


  68. VAKILI J, Sizemore L, Rebeiro PF, Tyndall B, et al
    Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators.
    PLoS One. 2022;17:e0270891.
    PubMed     Abstract available


  69. HYRINA A, Burdette D, Song Z, Ramirez R, et al
    Targeting lipid biosynthesis pathways for hepatitis B virus cure.
    PLoS One. 2022;17:e0270273.
    PubMed     Abstract available


  70. SCHORR O, Blach S, Thurnheer C, Ruis C, et al
    Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    PLoS One. 2022;17:e0272518.
    PubMed     Abstract available


    January 2021
  71. ATTIKU K, Bonney J, Agbosu E, Bonney E, et al
    Circulation of hepatitis delta virus and occult hepatitis B virus infection amongst HIV/HBV co-infected patients in Korle-Bu, Ghana.
    PLoS One. 2021;16:e0244507.
    PubMed     Abstract available


  72. SALYANI A, Shah J, Adam R, Otieno G, et al
    Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naive adults.
    PLoS One. 2021;16:e0244947.
    PubMed     Abstract available


  73. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    PubMed     Abstract available


  74. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    PubMed     Abstract available



  75. Retraction: An Occult Hepatitis B-Derived Hepatoma Cell Line Carrying Persistent Nuclear Viral DNA and Permissive for Exogenous Hepatitis B Virus Infection.
    PLoS One. 2021;16:e0246549.
    PubMed    


  76. KMUSH BL, Lu AM, Spillane T, Hruska B, et al
    Seroprevalence of hepatitis E virus antibodies in adults and children from upstate New York: A cross-sectional study.
    PLoS One. 2021;16:e0245850.
    PubMed     Abstract available


  77. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    PubMed     Abstract available


  78. HASHIMOTO S, Shirasaki T, Yamashita T, Iwabuchi S, et al
    DOCK11 and DENND2A play pivotal roles in the maintenance of hepatitis B virus in host cells.
    PLoS One. 2021;16:e0246313.
    PubMed     Abstract available


  79. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    PubMed     Abstract available


  80. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    PubMed     Abstract available


  81. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    PubMed     Abstract available


  82. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    PubMed     Abstract available


  83. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    PubMed     Abstract available


  84. LEE DY, Chae SJ, Cho SR, Choi W, et al
    Nationwide seroprevalence of hepatitis A in South Korea from 2009 to 2019.
    PLoS One. 2021;16:e0245162.
    PubMed     Abstract available


  85. TESFA T, Hawulte B, Tolera A, Abate D, et al
    Hepatitis B virus infection and associated risk factors among medical students in eastern Ethiopia.
    PLoS One. 2021;16:e0247267.
    PubMed     Abstract available


  86. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    PubMed     Abstract available


  87. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.
    PubMed    


  88. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    PubMed     Abstract available


  89. CHARATCHAROENWITTHAYA P, Sukonrut K, Korpraphong P, Pongpaibul A, et al
    Diffusion-weighted magnetic resonance imaging for the assessment of liver fibrosis in chronic viral hepatitis.
    PLoS One. 2021;16:e0248024.
    PubMed     Abstract available


  90. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    PubMed     Abstract available


  91. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    PubMed     Abstract available


  92. DAN-NWAFOR CC, Adeoye I, Aderemi K, Onuoha M, et al
    Serological markers and risk factors associated with Hepatitis B virus infection among Federal Capital Territory prison inmates, Nigeria: Should we be concerned?
    PLoS One. 2021;16:e0248045.
    PubMed     Abstract available


  93. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed     Abstract available


  94. ATALAY AA, Abebe RK, Dadhi AE, Bededa WK, et al
    Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia; health facility based cross-sectional study.
    PLoS One. 2021;16:e0249216.
    PubMed     Abstract available


  95. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed     Abstract available


  96. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    PubMed     Abstract available


  97. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    PubMed     Abstract available



  98. Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0250185.
    PubMed     Abstract available


  99. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    PubMed     Abstract available


  100. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
    Correction: Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    PLoS One. 2021;16:e0250536.
    PubMed     Abstract available


  101. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    PubMed     Abstract available


  102. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    PubMed     Abstract available


  103. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    PubMed     Abstract available


  104. ANTENEH ZA, Wondaye E, Mengesha EW
    Hepatitis B virus infection and its determinants among HIV positive pregnant women: Multicenter unmatched case-control study.
    PLoS One. 2021;16:e0251084.
    PubMed     Abstract available


  105. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
    Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
    PLoS One. 2021;16:e0250347.
    PubMed     Abstract available


  106. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    PubMed     Abstract available



  107. Correction: Correction: Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2021;16:e0251539.
    PubMed     Abstract available


  108. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    PubMed     Abstract available


  109. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    PubMed     Abstract available


  110. CHA HJ, Hwang J, Lee LE, Park Y, et al
    The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
    PLoS One. 2021;16:e0244950.
    PubMed     Abstract available


  111. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    PubMed     Abstract available


  112. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    PubMed     Abstract available


  113. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    PubMed     Abstract available


  114. MALAMBA SS, Muyinda H, Ogwang DM, Katamba A, et al
    Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda.
    PLoS One. 2021;16:e0251573.
    PubMed     Abstract available


  115. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    PubMed     Abstract available


  116. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed     Abstract available


  117. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed     Abstract available


  118. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed     Abstract available


  119. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    PubMed     Abstract available


  120. RASTOGI A, Chauhan S, Ramalingam A, Verma M, et al
    Capacity building of healthcare workers: Key step towards elimination of viral hepatitis in developing countries.
    PLoS One. 2021;16:e0253539.
    PubMed     Abstract available


  121. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    PubMed     Abstract available


  122. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    PubMed     Abstract available


  123. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    PubMed     Abstract available


  124. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    PubMed     Abstract available


  125. GOMES LC, Sanson MCG, Brainin P, de Melo MDCV, et al
    Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon.
    PLoS One. 2021;16:e0253752.
    PubMed     Abstract available


  126. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    PubMed     Abstract available


  127. HOA TN, Munshi SU, Ngoc KN, Ngoc CL, et al
    A tightly clustered hepatitis E virus genotype 1a is associated with endemic and outbreak infections in Bangladesh.
    PLoS One. 2021;16:e0255054.
    PubMed     Abstract available


  128. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available


  129. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    PubMed     Abstract available


  130. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    PubMed     Abstract available


  131. JOSHUA PE, Nwauzor CO, Odimegwu DC, Ukachukwu UG, et al
    Experimental and molecular predictions of the adjuvanticity of snail mucin on hepatitis B vaccine in albino mice.
    PLoS One. 2021;16:e0246915.
    PubMed     Abstract available


  132. RUTHERFORD L, Stark A, Ablona A, Klassen BJ, et al
    Health and well-being of trans and non-binary participants in a community-based survey of gay, bisexual, and queer men, and non-binary and Two-Spirit people across Canada.
    PLoS One. 2021;16:e0246525.
    PubMed     Abstract available


  133. ERIKSEN LL, Nielsen MA, Laursen TL, Deleuran B, et al
    Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis.
    PLoS One. 2021;16:e0255574.
    PubMed     Abstract available


  134. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    PubMed     Abstract available


  135. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    PubMed     Abstract available


  136. ISRAR M, Ali F, Nawaz A, Idrees M, et al
    Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
    PLoS One. 2021;16:e0255189.
    PubMed     Abstract available


  137. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    PubMed     Abstract available


  138. HEFZY EM, Hassuna NA, Shaker OG, Masoud M, et al
    miR-155 T/A (rs767649) and miR-146a A/G (rs57095329) single nucleotide polymorphisms as risk factors for chronic hepatitis B virus infection among Egyptian patients.
    PLoS One. 2021;16:e0256724.
    PubMed     Abstract available


  139. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    PubMed     Abstract available


  140. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    PubMed     Abstract available


  141. OSAMUDIAMEN FT, Akanbi OA, Oluwayelu DO, Bock CT, et al
    Serological evidence of avian HEV antibodies in apparently healthy chickens in southwest Nigeria.
    PLoS One. 2021;16:e0247889.
    PubMed     Abstract available


  142. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    PubMed     Abstract available


  143. GHOSH A, Onsager C, Mason A, Arriola L, et al
    The role of oxygen intake and liver enzyme on the dynamics of damaged hepatocytes: Implications to ischaemic liver injury via a mathematical model.
    PLoS One. 2021;16:e0230833.
    PubMed     Abstract available


  144. HAILE K, Timerga A, Mose A, Mekonnen Z, et al
    Hepatitis B vaccination status and associated factors among students of medicine and health sciences in Wolkite University, Southwest Ethiopia: A cross-sectional study.
    PLoS One. 2021;16:e0257621.
    PubMed     Abstract available


  145. QUAYE T, Narkwa PW, Domfeh SA, Kattah G, et al
    Immunosurveillance and molecular detection of hepatitis B virus infection amongst vaccinated children in the West Gonja District in Savanna Region of Ghana.
    PLoS One. 2021;16:e0257103.
    PubMed     Abstract available


  146. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    PubMed     Abstract available


  147. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    PubMed     Abstract available


  148. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    PubMed     Abstract available


  149. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    PubMed     Abstract available


  150. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    PubMed     Abstract available


  151. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
    An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
    PLoS One. 2021;16:e0250505.
    PubMed     Abstract available


  152. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
    Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
    PLoS One. 2021;16:e0257437.
    PubMed     Abstract available


  153. KANG SH, Cho DH, Choi J, Baik SK, et al
    Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.
    PLoS One. 2021;16:e0258229.
    PubMed     Abstract available


  154. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
    PLoS One. 2021;16:e0258143.
    PubMed     Abstract available


  155. BALEGHA AN, Yidana A, Abiiro GA
    Knowledge, attitude and practice of hepatitis B infection prevention among nursing students in the Upper West Region of Ghana: A cross-sectional study.
    PLoS One. 2021;16:e0258757.
    PubMed     Abstract available


  156. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
    Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
    PLoS One. 2021;16:e0257975.
    PubMed     Abstract available


  157. KAMALI I, Barnhart DA, Ndahimana JD, Noor K, et al
    Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study.
    PLoS One. 2021;16:e0257917.
    PubMed     Abstract available


  158. PEDARRIEU A, El Mellouli F, Khallouki H, Zro K, et al
    External quality assessment of Rift Valley fever diagnosis in countries at risk of the disease: African, Indian Ocean and Middle-East regions.
    PLoS One. 2021;16:e0251263.
    PubMed     Abstract available


  159. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
    Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
    PLoS One. 2021;16:e0249061.
    PubMed     Abstract available


  160. OLAKUNDE BO, Adeyinka DA, Olakunde OA, Uthman OA, et al
    A systematic review and meta-analysis of the prevalence of hepatitis B virus infection among pregnant women in Nigeria.
    PLoS One. 2021;16:e0259218.
    PubMed     Abstract available


  161. KLOK S, van Dulm E, Boyd A, Generaal E, et al
    Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
    PLoS One. 2021;16:e0258932.
    PubMed     Abstract available


  162. PAN CQ, Chang TT, Bae SH, Brunetto M, et al
    Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
    PLoS One. 2021;16:e0251552.
    PubMed     Abstract available


  163. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
    Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0260179.
    PubMed     Abstract available


  164. STEPHENS Z, O'Brien D, Dehankar M, Roberts LR, et al
    Exogene: A performant workflow for detecting viral integrations from paired-end next-generation sequencing data.
    PLoS One. 2021;16:e0250915.
    PubMed     Abstract available


  165. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
    Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
    PLoS One. 2021;16:e0253759.
    PubMed     Abstract available


  166. CASTRO LS, Rezende GR, Pires Fernandes FR, Bandeira LM, et al
    HAV infection in Brazilian men who have sex with men: The importance of surveillance to avoid outbreaks.
    PLoS One. 2021;16:e0256818.
    PubMed     Abstract available


  167. TOWNSHEND-BULSON L, Roik E, Barbour Y, Bruden DJT, et al
    The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    PLoS One. 2021;16:e0260970.
    PubMed     Abstract available


  168. YU S, Chen W, Jiang Z
    Platelet count/spleen volume ratio has a good predictive value for esophageal varices in patients with hepatitis B liver cirrhosis.
    PLoS One. 2021;16:e0260774.
    PubMed     Abstract available


  169. HERNANDEZ-SUAREZ G, Saha D, Lodrono K, Boonmahittisut P, et al
    Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review.
    PLoS One. 2021;16:e0258659.
    PubMed     Abstract available


  170. GUAN TH, Htut HN, Davison CM, Sebastian S, et al
    Implementation of a neonatal hepatitis B immunization program in rural Karenni State, Myanmar: A mixed-methods study.
    PLoS One. 2021;16:e0261470.
    PubMed     Abstract available


  171. GARCIA-HEROLA A, Dominguez-Hernandez R, Casado MA
    Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
    PLoS One. 2021;16:e0260608.
    PubMed     Abstract available


  172. ABGHOUR S, Mouahid M, Darkaoui S, Berrada J, et al
    Pathogenicity of field strain of fowl aviadenovirus serotype 11 isolated from chickens with inclusion body hepatitis in Morocco.
    PLoS One. 2021;16:e0261284.
    PubMed     Abstract available


  173. NERSESOV A, Gusmanov A, Crape B, Junusbekova G, et al
    Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.
    PLoS One. 2021;16:e0261155.
    PubMed     Abstract available


  174. BITTY-ANDERSON AM, Ferre V, Gbeasor-Komlanvi FA, Tchankoni MK, et al
    Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
    PLoS One. 2021;16:e0259891.
    PubMed     Abstract available


  175. DE VOS CJ, Hennen WHGJ, van Roermund HJW, Dhollander S, et al
    Assessing the introduction risk of vector-borne animal diseases for the Netherlands using MINTRISK: A Model for INTegrated RISK assessment.
    PLoS One. 2021;16:e0259466.
    PubMed     Abstract available


  176. SUZUKI T, Matsuura K, Nagura Y, Iio E, et al
    Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection.
    PLoS One. 2021;16:e0261878.
    PubMed     Abstract available


  177. CHEN Q, Liu J, He Y, Yang L, et al
    Prevalence of HBsAg among reproductive age couples in Chongqing: A population-based, cross-sectional study.
    PLoS One. 2021;16:e0260028.
    PubMed     Abstract available


  178. AZIT NA, Sahran S, Voon Meng L, Subramaniam M, et al
    Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.
    PLoS One. 2021;16:e0260675.
    PubMed     Abstract available


  179. NOUANTHONG P, Hefele L, Keokhamphue J, Sorrasin V, et al
    Analyses of blood donor samples from eight provinces in Lao PDR suggest considerable variation concerning HBV exposure and carriage.
    PLoS One. 2021;16:e0259814.
    PubMed     Abstract available


    January 2020
  180. MARCELLIN P, Xie Q, Woon Paik S, Flisiak R, et al
    Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
    PLoS One. 2020;15:e0230893.
    PubMed     Abstract available


  181. KHAN HU, Khan S, Shah MA, Attaullah S, et al
    Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients.
    PLoS One. 2020;15:e0231480.
    PubMed     Abstract available


  182. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    PubMed     Abstract available


  183. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    PubMed     Abstract available


  184. PRINSENBERG T, Rebers S, Boyd A, Zuure F, et al
    Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection.
    PLoS One. 2020;15:e0231385.
    PubMed     Abstract available


  185. CHIU SM, Tsai MC, Lin CY, Chen CH, et al
    Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.
    PLoS One. 2020;15:e0231102.
    PubMed     Abstract available


  186. KRACHT PAM, Arends JE, Hoepelman AIM, Vervoort SCJM, et al
    The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.
    PLoS One. 2020;15:e0230756.
    PubMed     Abstract available


  187. PRATEDRAT P, Chuaypen N, Nimsamer P, Payungporn S, et al
    Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0232211.
    PubMed     Abstract available


  188. DORTEY BA, Anaba EA, Lassey AT, Damale NKR, et al
    Seroprevalence of Hepatitis B virus infection and associated factors among pregnant women at Korle-Bu Teaching Hospital, Ghana.
    PLoS One. 2020;15:e0232208.
    PubMed     Abstract available


  189. ADAM A, Fusheini A
    Knowledge, risk of infection, and vaccination status of hepatitis B virus among rural high school students in Nanumba North and South Districts of Ghana.
    PLoS One. 2020;15:e0231930.
    PubMed     Abstract available


  190. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    PubMed     Abstract available


  191. RAMDASI AY, Arankalle VA
    The expression patterns of immune response genes in the Peripheral Blood Mononuclear cells of pregnant women presenting with subclinical or clinical HEV infection are different and trimester-dependent: A whole transcriptome analysis.
    PLoS One. 2020;15:e0228068.
    PubMed     Abstract available


  192. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    PubMed     Abstract available


  193. HOSKING K, Stewart G, Mobsby M, Skov S, et al
    Data linkage and computerised algorithmic coding to enhance individual clinical care for Aboriginal people living with chronic hepatitis B in the Northern Territory of Australia - Is it feasible?
    PLoS One. 2020;15:e0232207.
    PubMed     Abstract available


  194. BANCHA B, Kinfe AA, Chanko KP, Workie SB, et al
    Prevalence of hepatitis B viruses and associated factors among pregnant women attending antenatal clinics in public hospitals of Wolaita Zone, South Ethiopia.
    PLoS One. 2020;15:e0232653.
    PubMed     Abstract available


  195. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Treatment and re-treatment results of HCV patients in the DAA era.
    PLoS One. 2020;15:e0232773.
    PubMed     Abstract available


  196. PHILIP G, Djerboua M, Carlone D, Flemming JA, et al
    Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data.
    PLoS One. 2020;15:e0229218.
    PubMed     Abstract available


  197. AKHTAR S, Nasir JA, Usman M, Sarwar A, et al
    The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0232931.
    PubMed     Abstract available


  198. RUIZ-EXTREMERA A, Diaz-Alcazar MDM, Munoz-Gamez JA, Cabrera-Lafuente M, et al
    Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.
    PLoS One. 2020;15:e0233528.
    PubMed     Abstract available


  199. NGUYEN DT, Tran TTT, Nghiem NM, Le PT, et al
    Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PLoS One. 2020;15:e0233446.
    PubMed     Abstract available


  200. POILIL SURENDRAN S, George Thomas R, Moon MJ, Park R, et al
    Effect of hepato-toxins in the acceleration of hepatic fibrosis in hepatitis B mice.
    PLoS One. 2020;15:e0232619.
    PubMed     Abstract available


  201. ISMAIL MB, Al Kassaa I, El Safadi D, Al Omari S, et al
    Prevalence of anti-hepatitis E virus IgG antibodies in sera from hemodialysis patients in Tripoli, Lebanon.
    PLoS One. 2020;15:e0233256.
    PubMed     Abstract available


  202. JEPKEMEI KB, Ochwoto M, Swidinsky K, Day J, et al
    Characterization of occult hepatitis B in high-risk populations in Kenya.
    PLoS One. 2020;15:e0233727.
    PubMed     Abstract available


  203. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    PubMed     Abstract available


  204. LIN WC, Lin YS, Chang CW, Chang CW, et al
    Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0233212.
    PubMed     Abstract available


  205. ABESIG J, Chen Y, Wang H, Sompo FM, et al
    Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0234348.
    PubMed     Abstract available


  206. MORISHITA N, Sakamori R, Yamada T, Kai Y, et al
    Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    PLoS One. 2020;15:e0234811.
    PubMed     Abstract available


  207. CABEZAS C, Trujillo O, Gonzales-Vivanco A, Benites Villafane CM, et al
    Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2020;15:e0234273.
    PubMed     Abstract available


  208. DURACINSKY M, Thonon F, Bun S, Ben Nasr I, et al
    Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study.
    PLoS One. 2020;15:e0235260.
    PubMed     Abstract available



  209. Retraction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2020;15:e0235375.
    PubMed    


  210. ZHENG Y, Zhang L, Zhu X, Guo G, et al
    A comparative study of two methods to predict the incidence of hepatitis B in Guangxi, China.
    PLoS One. 2020;15:e0234660.
    PubMed     Abstract available


  211. TENG CF, Tsai HW, Li TC, Wang T, et al
    Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues.
    PLoS One. 2020;15:e0234773.
    PubMed     Abstract available


  212. BRAIN D, Mitchell J, O'Beirne J
    Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.
    PLoS One. 2020;15:e0234577.
    PubMed     Abstract available


  213. ASEMAHAGN MA
    Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia.
    PLoS One. 2020;15:e0234822.
    PubMed     Abstract available


  214. LEE MH, Lee GA, Lee SH, Park YH, et al
    A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: Back to basics of infection control.
    PLoS One. 2020;15:e0229911.
    PubMed     Abstract available


  215. TRAEGER MW, Pedrana AE, van Santen DK, Doyle JS, et al
    The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    PLoS One. 2020;15:e0235445.
    PubMed     Abstract available


  216. ZHANG Y, Gao Z, Wang S, Liu J, et al
    Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion.
    PLoS One. 2020;15:e0235612.
    PubMed     Abstract available


  217. COPPOCK D, Chou E, Gracely E, Gross R, et al
    Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.
    PLoS One. 2020;15:e0235778.
    PubMed     Abstract available


  218. SSEKAMATTE T, Mukama T, Kibira SPS, Ndejjo R, et al
    Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda.
    PLoS One. 2020;15:e0235470.
    PubMed     Abstract available


  219. TRONINA O, Gotlib J, Malkowski P, Jaworski M, et al
    Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.
    PLoS One. 2020;15:e0235764.
    PubMed     Abstract available


  220. JARGALSAIKHAN G, Eichner M, Boldbaatar D, Bat-Ulzii P, et al
    Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.
    PLoS One. 2020;15:e0235036.
    PubMed     Abstract available


  221. LI H, Marks KM, Talal AH, van Seggelen WO, et al
    Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing.
    PLoS One. 2020;15:e0235237.
    PubMed     Abstract available


  222. SALINES M, Andraud M, Rose N, Widgren S, et al
    A between-herd data-driven stochastic model to explore the spatio-temporal spread of hepatitis E virus in the French pig production network.
    PLoS One. 2020;15:e0230257.
    PubMed     Abstract available


  223. TRAN HTL, Morikawa K, Anggakusuma, Zibi R, et al
    OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    PLoS One. 2020;15:e0236447.
    PubMed     Abstract available


  224. PEREIRA FM, Almeida MDCC, Santos FLN, Carreiro RP, et al
    Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.
    PLoS One. 2020;15:e0223087.
    PubMed     Abstract available


  225. BERG MG, Olivo A, Forberg K, Harris BJ, et al
    Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses.
    PLoS One. 2020;15:e0236046.
    PubMed     Abstract available


  226. SHAWON MA, Yousuf MAK, Raheem E, Ahmed S, et al
    Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.
    PLoS One. 2020;15:e0232121.
    PubMed     Abstract available


  227. PALAYEW A, Stumo SR, Cooke GS, Hutchinson SJ, et al
    The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    PLoS One. 2020;15:e0235715.
    PubMed     Abstract available


  228. KOC OM, Kremer C, Hens N, Bielen R, et al
    Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium.
    PLoS One. 2020;15:e0234740.
    PubMed     Abstract available


  229. VERSTER AM, Liang JE, Rostal MK, Kemp A, et al
    Selected wetland soil properties correlate to Rift Valley fever livestock mortalities reported in 2009-10 in central South Africa.
    PLoS One. 2020;15:e0232481.
    PubMed     Abstract available


  230. CABEZAS C, Trujillo O, Balbuena J, Peceros FM, et al
    Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B.
    PLoS One. 2020;15:e0236993.
    PubMed     Abstract available


  231. NGWAGA T, Kong L, Lin D, Schoborg C, et al
    Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PLoS One. 2020;15:e0237162.
    PubMed     Abstract available


  232. JEONG GU, Ahn BY, Jung J, Kim H, et al
    A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants.
    PLoS One. 2020;15:e0236704.
    PubMed     Abstract available


  233. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    PubMed     Abstract available


  234. YEN HH, Su PY, Zeng YH, Liu IL, et al
    Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
    PLoS One. 2020;15:e0237582.
    PubMed     Abstract available


  235. YU HC, Lin KH, Tsay FW, Tsai TJ, et al
    Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies.
    PLoS One. 2020;15:e0237586.
    PubMed     Abstract available


  236. DE VILLIERS MJ, Gamkrelidze I, Hallett TB, Nayagam S, et al
    Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models.
    PLoS One. 2020;15:e0237525.
    PubMed     Abstract available


  237. BARUTI K, Lentz K, Anderson M, Ajibola G, et al
    Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana.
    PLoS One. 2020;15:e0237252.
    PubMed     Abstract available


  238. BOBARDT M, Hansson MJ, Mayo P, Ure D, et al
    Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
    PLoS One. 2020;15:e0237236.
    PubMed     Abstract available


  239. FAGUNDES RN, Ferreira LEVVC, Pace FHL
    Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PLoS One. 2020;15:e0237005.
    PubMed     Abstract available


  240. MINOSSE C, Messina F, Garbuglia AR, Meschi S, et al
    Origin of HAV strains responsible for 2016-2017 outbreak among MSM: Viral phylodynamics in Lazio region.
    PLoS One. 2020;15:e0234010.
    PubMed     Abstract available


  241. ASHHAB AA, Rodin H, Campos M, Abu-Sulb A, et al
    Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
    PLoS One. 2020;15:e0237398.
    PubMed     Abstract available


  242. DUCHESNE L, Hejblum G, Njouom R, Toure Kane C, et al
    Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    PLoS One. 2020;15:e0238035.
    PubMed     Abstract available


  243. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    PubMed     Abstract available


  244. ANDERSON ES, Russell C, Basham K, Montgomery M, et al
    High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department.
    PLoS One. 2020;15:e0233927.
    PubMed     Abstract available


  245. HANSON J, Fox M, Anderson A, Fox P, et al
    Chronic hepatitis B in remote, tropical Australia; successes and challenges.
    PLoS One. 2020;15:e0238719.
    PubMed     Abstract available


  246. NIELSEN S, Hansen JF, Hay G, Cowan S, et al
    Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
    PLoS One. 2020;15:e0238203.
    PubMed     Abstract available


  247. CHOI YH, Zhang X, Srinivasamoorthy G, Purdy MA, et al
    Transcriptome analysis in rhesus macaques infected with hepatitis E virus genotype 1/3 infections and genotype 1 re-infection.
    PLoS One. 2020;15:e0237618.
    PubMed     Abstract available


  248. READY E, Habecker P, Abadie R, Khan B, et al
    Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs.
    PLoS One. 2020;15:e0235124.
    PubMed     Abstract available


  249. LIU L, Hou J, Xu Y, Qin L, et al
    PD-L1 upregulation by IFN-alpha/gamma-mediated Stat1 suppresses anti-HBV T cell response.
    PLoS One. 2020;15:e0228302.
    PubMed     Abstract available


  250. LI J, Abosmaha E, Coffin CS, Labonte P, et al
    Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes.
    PLoS One. 2020;15:e0239153.
    PubMed     Abstract available


  251. GUO Y, Feng Y, Qu F, Zhang L, et al
    Prediction of hepatitis E using machine learning models.
    PLoS One. 2020;15:e0237750.
    PubMed     Abstract available


  252. ADEYEMI OA, Itanyi IU, Ozigbu CE, Stadnick N, et al
    Sero-prevalence and determinants of Hepatitis B among a cohort of HIV-infected women of reproductive age in Nigeria.
    PLoS One. 2020;15:e0236456.
    PubMed     Abstract available


  253. TAMANDJOU TCHUEM CR, Brandt L, Nel ER, Cotton MF, et al
    Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
    PLoS One. 2020;15:e0238839.
    PubMed     Abstract available


  254. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    PubMed     Abstract available


  255. GANDJOUR A
    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    PubMed     Abstract available


  256. INGASIA LAO, Kostaki EG, Paraskevis D, Kramvis A, et al
    Global and regional dispersal patterns of hepatitis B virus genotype E from and in Africa: A full-genome molecular analysis.
    PLoS One. 2020;15:e0240375.
    PubMed     Abstract available


  257. HOFFMANN P, Behnisch R, Gsenger J, Schnitzler P, et al
    Hepatitis E seroprevalence in a German cohort of patients with inflammatory bowel diseases.
    PLoS One. 2020;15:e0239825.
    PubMed     Abstract available


  258. THOMSEN H, Li X, Sundquist K, Sundquist J, et al
    Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases.
    PLoS One. 2020;15:e0240794.
    PubMed     Abstract available


  259. BAYU H, Elias B, Abdisa S, Tune A, et al
    Post exposure prophylaxis coverage, vertical transmission and associated factors among hepatitis B exposed newborns delivered at Arsi zone health institutions, 2019.
    PLoS One. 2020;15:e0238987.
    PubMed     Abstract available


  260. AN J, Kim HI, Chang S, Shim JH, et al
    Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma.
    PLoS One. 2020;15:e0238078.
    PubMed     Abstract available


  261. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available


  262. ABDELLA S, Moshago Berheto T, Tolera G, Belete W, et al
    Sero-prevalence of transfusion transmittable infections: HIV, Hepatitis B, C and Treponema pallidum and associated factors among blood donors in Ethiopia: A retrospective study.
    PLoS One. 2020;15:e0241086.
    PubMed     Abstract available


  263. AWOKE N, Mulgeta H, Lolaso T, Tekalign T, et al
    Full-dose hepatitis B virus vaccination coverage and associated factors among health care workers in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0241226.
    PubMed     Abstract available


  264. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    PubMed     Abstract available


  265. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    PubMed     Abstract available


  266. ABE K, Fujita M, Hayashi M, Takahashi A, et al
    Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis.
    PLoS One. 2020;15:e0239481.
    PubMed     Abstract available


  267. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    PubMed     Abstract available


  268. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    PubMed     Abstract available


  269. KASHIWAKURA JI, Saitoh K, Ihara T, Sasaki Y, et al
    Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    PLoS One. 2020;15:e0241440.
    PubMed     Abstract available


  270. GEZAHEGN LK, Argaw E, Assefa B, Geberesilassie A, et al
    Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study.
    PLoS One. 2020;15:e0241346.
    PubMed     Abstract available


  271. PEREZ-RAMIREZ E, Cano-Gomez C, Llorente F, Adzic B, et al
    External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories of the Mediterranean and Black Sea regions.
    PLoS One. 2020;15:e0239478.
    PubMed     Abstract available


  272. AIYAMA T, Orimo T, Yokoo H, Ohata T, et al
    Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis.
    PLoS One. 2020;15:e0239462.
    PubMed     Abstract available


  273. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available


  274. PATEL NH, Meier-Stephenson V, Genetu M, Damtie D, et al
    Prevalence and genetic variability of occult hepatitis B virus in a human immunodeficiency virus positive patient cohort in Gondar, Ethiopia.
    PLoS One. 2020;15:e0242577.
    PubMed     Abstract available


  275. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available


  276. CHIESA A, Ochola E, Oreni L, Vassalini P, et al
    Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?
    PLoS One. 2020;15:e0242278.
    PubMed     Abstract available


  277. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available


  278. TENG CF, Li TC, Huang HY, Chan WL, et al
    Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection.
    PLoS One. 2020;15:e0242748.
    PubMed     Abstract available


  279. SHRESTHA DB, Khadka M, Khadka M, Subedi P, et al
    Hepatitis B vaccination status and knowledge, attitude, and practice regarding Hepatitis B among preclinical medical students of a medical college in Nepal.
    PLoS One. 2020;15:e0242658.
    PubMed     Abstract available


  280. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    PubMed     Abstract available


  281. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    PubMed     Abstract available


  282. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    PubMed     Abstract available


  283. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    PubMed     Abstract available


  284. MANATHUNGE A, Barbaric J, Mestrovic T, Beneragama S, et al
    HIV prevalence, sexual risk behaviours and HIV testing among female sex workers in three cities in Sri Lanka: Findings from respondent-driven sampling surveys.
    PLoS One. 2020;15:e0239951.
    PubMed     Abstract available


  285. DUMAIDI K, Qaraqe H, Al-Jawabreh A, Abu-Helu R, et al
    Genetic diversity, haplotype analysis, and risk factor assessment of hepatitis A virus isolates from the West Bank, Palestine during the period between 2014 and 2016.
    PLoS One. 2020;15:e0240339.
    PubMed     Abstract available


  286. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    PubMed     Abstract available


  287. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available


  288. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available


  289. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    PubMed     Abstract available


  290. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    PubMed     Abstract available


  291. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    PubMed     Abstract available


  292. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    PubMed     Abstract available


  293. AFAA TJ, Amegan-Aho KH, Dono MT, Odei E, et al
    Clinical characteristics of paediatric autoimmune hepatitis at a referral hospital in Sub Saharan Africa.
    PLoS One. 2020;15:e0239964.
    PubMed     Abstract available


  294. TUCKER CJ, Melocik KA, Anyamba A, Linthicum KJ, et al
    Reanalysis of the 2000 Rift Valley fever outbreak in Southwestern Arabia.
    PLoS One. 2020;15:e0233279.
    PubMed     Abstract available


  295. HEFELE L, Syphan S, Xayavong D, Homsana A, et al
    Timeliness of immunisation with the pentavalent vaccine at different levels of the health care system in the Lao People's Democratic Republic: A cross-sectional study.
    PLoS One. 2020;15:e0242502.
    PubMed     Abstract available


  296. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: